ATF3 and metabolic dysfunction-associated steatotic liver disease: In summary, this study elucidates that the novel SCD1 inhibitor E6446 suppresses hepatic lipogenesis and adipogenic differentiation via SCD1-ATF3 signaling, providing insights into the role of E6446 in the treatment of NAFLD through the liver-adipose liver axis.